PedAM
Pediatric Disease Annotations & Medicines
| Disease | lung cancer |
| Phenotype | C0026846|muscle wasting |
| Sentences | 1 |
| PubMedID- 24490605 | Enobosarm has received fast track designation by the us fda and results from the phase iii trials power1 and power2 will help determine approval for use in the prevention and treatment of muscle wasting in patients with non-small-cell lung cancer. |
Page: 1